Form 4: Pliant Therapeutics Director Granted 30,000 Stock Options

Pliant Therapeutics, Inc. director Hoyoung Huh was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Summary

• Hoyoung Huh, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $1.61 per share.
• The options have an expiration date of June 5, 2035.
• The vesting schedule for the options is as follows: 25% on October 1, 2025, 25% on January 1, 2026, 25% on April 1, 2026, and the remaining 25% on the earlier of the one-year anniversary of the June 5, 2025 grant date or the next annual meeting of stockholders.
• Vesting is contingent upon Mr. Huh's continued service as a Director to the Issuer through each respective vesting date or annual meeting.
• The filing also includes a Limited Power of Attorney, dated June 5, 2025, authorizing specific individuals to execute SEC forms on behalf of Hoyoung Huh.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably. It indicates continued commitment from the board member. However, it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term value creation.
• The exercise price of $1.61 is significantly lower than the current market price of PLRX (assuming typical option grants are at or near market price on grant date, though not explicitly stated as such, it's a common practice for incentive options), providing potential upside for the director.

Negatives

• No specific negatives are identified in this Form 4 filing, which primarily reports an insider transaction.

Risks

• The vesting of the options is subject to the reporting person's continued service to the Issuer as a Director, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Management Comments

• The filing indicates that the stock option grant to Director Hoyoung Huh is part of the company's compensation structure, aligning his interests with long-term shareholder value.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This practice aims to incentivize long-term commitment and performance by linking personal wealth to the company's stock performance. Such grants are standard mechanisms for attracting and retaining experienced board members in a competitive sector.

Comparison to Industry Standards

• The grant of 30,000 stock options to a director is a typical form of equity compensation in the biotech industry, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, where director compensation often includes a mix of cash and equity to align interests with shareholders.
• The vesting schedule, with a significant portion vesting over the first year and the remainder tied to continued service, is standard for incentivizing ongoing commitment, similar to equity grants observed at peer companies such as Vertex Pharmaceuticals or Amgen.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Hoyoung Huh, a Director of Pliant Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The granted stock options will vest in tranches on October 1, 2025, January 1, 2026, April 1, 2026, and the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Vesting Schedule, SEC Filing, Biotechnology